AIxMed
AIxMed is an AI-native digital cytology company that builds computer vision software (AIxURO, AIxTHY, AIxPAP, AIxPUL) to detect cancer cells in urine, thyroid, cervical, and pulmonary specimens for pathology laboratories, urology practices, and reference labs via direct enterprise sales and channel partners.
- Company typePrivate
- Founded2018
- HeadquartersSanta Clara, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What AIxMed does
AIxMed, Inc. is a Santa Clara, Delaware-incorporated, venture-backed private company founded in 2018 by Samuel Chen and Dr. Tien-Jen Liu to apply machine learning and computer vision to cancer cytology. Its core product, AIxURO, is an FDA-designated Research Use Only software platform that analyzes whole slide images (WSI) of urine cytology specimens to identify suspicious and atypical urothelial cells using The Paris System (TPS 2.0) criteria, generating quantitative outputs such as N/C ratios, nuclear area, and ranked top-24 cell galleries. The platform is differentiated by proprietary multi-plane Z-stacking scanning and heuristic scanning algorithms that capture abnormal cells at all depths in 3D cytology samples while reducing scan time and file size versus conventional Z-stacking.
The company is extending this architecture across a four-product portfolio: AIxURO (urine/bladder, commercially available as RUO), AIxTHY (thyroid, near-term RUO, Bethesda System), and AIxPAP (cervical) and AIxPUL (pulmonary), both in development. The platform integrates with multiple slide scanners (Hamamatsu, Leica Aperio, 3DHistech, Mikroscan, Huron), preparation methods (ThinPrep, SurePath, CytoRich, Cytospin), and laboratory information systems via an open API, with file format support for .tiff, .svs, and jpeg.
AIxMed generates revenue by licensing its AI software to pathology laboratories, healthcare systems, and reference labs, primarily through subscription or enterprise licensing bundled with channel partnerships. Distribution combines direct enterprise sales (demo/consultation model) with channel partners including Lumea (FDA-cleared digital pathology platform), PathNet, CorePlus, Superb Diagnostics, and Bioptická Laboratoř, plus an education partnership with the American Society for Cytology (ASCT). The company has raised approximately $11M+ across disclosed rounds in 2021-2023 and reports 11-50 employees.
AIxMed firmographics
Firmographics- Name
- AIxMed
- Legal name
- AIxMed, Inc.
- Website
- https://aixmed.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AIxMed is an AI-native digital cytology company that builds computer vision software (AIxURO, AIxTHY, AIxPAP, AIxPUL) to detect cancer cells in urine, thyroid, cervical, and pulmonary specimens for pathology laboratories, urology practices, and reference labs via direct enterprise sales and channel partners.
- Ownership category
- akta.pro rank
AIxMed industry classification
Industry- Product category
- AI Digital Pathology Software
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industries
- Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Medical Imaging AI (HDAAAEAH), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where AIxMed is headquartered
LocationHeadquarters
- HQ city
- Santa Clara
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AIxMed business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- AI Software Platform Licensing: AIxMed generates revenue through licensing its AI-powered computational cytology software platform (AIxURO, AIxTHY) to pathology laboratories and healthcare systems. The software is currently designated Research Use Only (RUO), with the company working toward FDA submission for clinical diagnostic use. Revenue model appears to follow SaaS/subscription licensing with integration into laboratory digital workflows.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
AIxMed product offering
Product offeringCore offering
AIxMed develops and sells AI-powered computational digital cytology software platforms that analyze whole slide images (WSI) to detect cancer cells. Its lead product, AIxURO, performs AI-assisted urine cytology analysis for bladder cancer detection using The Paris System (TPS 2.0) criteria, identifying suspicious and atypical urothelial cells with quantitative measurements. The portfolio also includes AIxTHY for thyroid cancer detection (FNAC analysis using the Bethesda System), with AIxPAP (cervical) and AIxPUL (lung) in development. The platform integrates with multiple slide scanners and Laboratory Information Systems via an open API.
Product overview
AIxMed offers a suite of AI-powered computational digital cytology platforms for cancer detection across multiple tissue types. The product portfolio includes AIxURO (commercially available for Research Use Only) for urine cytology and bladder cancer detection, AIxTHY (in development) for thyroid cytology, AIxPAP (in development) for cervical cancer screening, and AIxPUL (in development) for pulmonary cytology and lung cancer detection. The platforms combine whole slide imaging, advanced computer vision algorithms, and quantitative metrics following established cytology reporting standards (The Paris System for urine cytology, The Bethesda System for thyroid cytology) to assist pathologists in identifying abnormal cells, improving diagnostic accuracy, and enhancing workflow efficiency. All current products are designated For Research Use Only (RUO), not for use in diagnostic procedures.
Differentiator
Problem solved
Functional benefit
Brands
- AIxURO: AI-powered software for urinary cytology targeting bladder cancer detection, using The Paris System (TPS) criteria.
- AIxTHY
- AIxPAP
- AIxPUL
Products and services
- AIxURO AI-powered digital cytology software for urine cytology analysis targeting bladder cancer detection. Uses The Paris System (TPS 2.0) criteria to identify suspicious (SHGUC/HGUC) and atypical (AUC) urothelial cells, providing quantitative statistics including N/C ratios and nuclear areas in a gallery view for pathologist review. Reduces diagnostic review time by 50-80% and achieves up to 93.7% concordance with manual microscopy in validation studies. Currently designated Research Use Only (RUO).
- AIxTHY AI-powered digital cytology software for thyroid cancer diagnosis. Analyzes fine needle aspiration cytology (FNAC) samples using the Bethesda System (TBSRTC) to identify suspicious cells, classify nodules by cell type (follicular, oncocytic, histiocytes, lymphocytes, colloid), and distinguish benign from malignant nodules with quantitative scoring.
- AIxPAP AI-powered digital cytology solution for cervical cancer detection, currently in development. Will analyze cervical cytology specimens to improve cancer diagnosis using established screening standards.
- AIxPUL AI-powered digital cytology solution for pulmonary cytology and lung cancer detection, currently in development. Intended to empower precision in lung cancer detection.
Quantifiable outcome
- 50-80% reduction in diagnostic review time
- +6 more outcomes
Companies that use AIxMed
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
AIxMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration13 records
AI capability5 records
Feature5 records
AIxMed partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor and core.
- Superb DiagnosticsminorSuperb Dx and AIxMed announced reference lab service collaboration to integrate AIxMed's AIxURO technology into Superb Dx's digital pathology platform for urine cytology analysis. AI solution identifies suspicious and atypical cells using The Paris System (TPS 2.0) standards to improve accuracy and workflow efficiency in urothelial cell assessment for the urology market. AIxURO is currently designated as Research Use Only.
- CorePluscoreCorePlus, a healthcare technology company based in San Juan, Puerto Rico, implemented AIxURO to enhance bladder cancer detection through improved urine cytology analysis. The platform analyzes whole slide images and presents abnormal cells following The Paris System diagnostic standards, reducing diagnostic review time by 50-80% while maintaining consistent accuracy. Technology aims to improve patient outcomes through earlier detection and reduced reliance on invasive cystoscopy.
- American Society for Cytology (ASCT)minorAIxMed and ASCT partnered to enhance cytology training with AIxMed's AIxURO software. Collaboration aims to integrate AI technology into educational workflows to advance diagnostic accuracy and efficiency. AIxURO analyzes urine cytology specimens to improve bladder cancer diagnosis.
- PathNetcoreAIxMed and PathNet announced strategic partnership to enhance digital pathology services with AIxURO for improving bladder cancer diagnostics and workflow efficiency. Collaboration focuses on integrating AI-powered urine cytology analysis to support clinical decision-making and reduce invasive procedures.
- Bioptická LaboratořminorAIxMed and Bioptická Laboratoř announced strategic collaboration to advance AI-powered cytology in Europe. European implementation resulted in 30-50% faster workflow speed, improved sensitivity, and objective data for atypical cases.
- LumeacoreAIxMed and Lumea partnered to integrate AIxURO urine cytology diagnostic tool into Lumea's FDA-cleared digital pathology platform for the U.S. urology market. AIxURO uses The Paris System to identify suspicious and atypical cells from non-invasive urine samples, aiming to improve bladder cancer diagnostic accuracy and reduce reliance on invasive cystoscopies. The partnership expands Lumea's AI offerings and provides AIxMed access to Lumea's established digital pathology ecosystem.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
AIxMed competitors and assessment
Company assessmentDirect peers
- Paige.AI: AI-native digital pathology company applying deep learning to whole-slide images for cancer detection across multiple tissue types. Directly comparable in applying computer vision to WSI for diagnostic decision support, though Paige is more advanced in prostate and broader oncology indications.
- Ibex Medical Analytics: AI-powered cancer diagnostics for pathology, with deployed clinical products for breast, prostate, and gastric biopsy detection. Closely comparable as an AI pathology vendor selling into reference labs and health systems with FDA/CE-cleared products.
- PathAI: AI platform for pathology with both diagnostic products and pharma research offerings. Comparable as a direct AI-pathology competitor serving labs and biopharma, with overlapping WSI computer-vision technology.
Broad incumbents
- Lumea: FDA-cleared digital pathology platform integrating AIxURO for the U.S. urology market. Comparable as a broader digital pathology platform that bundles AIxMed's AI, and a partner/channel rather than pure competitor in the cytology niche.
- Roche Digital Pathology: Operates the widely deployed uPath/VENTANA digital pathology platform with scanners, image management, and AI partnerships. Comparable as a large incumbent whose installed base and scanner ecosystem could bundle competing AI cytology capabilities.
- Hologic: Maker of ThinPrep liquid-based cytology preparation, the dominant platform in non-gyn cytology and integrated with AIxMed. Comparable as a broad incumbent that controls upstream cytology prep and could internalize or bundle cytology AI.
- Danaher / Leica Biosystems: Owns Aperio digital pathology scanners and staining platforms used in many of the same labs AIxMed targets. Comparable as a broad incumbent across the pathology workflow whose scanner franchise is a key integration point for AIxMed.
- Hamamatsu Photonics: Manufacturer of NanoZoomer whole-slide scanners — one of the scanners AIxMed integrates with. Comparable as an incumbent WSI scanner vendor whose hardware ecosystem underpins cytology AI workflows.
Emerging players
- VolitionRx: Diagnostics company developing blood-based and other cancer-detection tests including for colorectal and other cancers. Comparable as an emerging player in cancer diagnostics but with a different specimen type (blood/serum vs. cytology).
- Mindpeak: AI pathology company focused on image-analysis workflows for diagnostic and pharma use. Comparable as a niche/emerging AI-pathology vendor with overlapping computer-vision approach and target labs, though smaller menu than AIxMed.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
AIxMed social profiles
Digital presenceAIxMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
AIxMed leadership team
Management profileNumber of profiles
Profiles4 records
AIxMed funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AIxMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AIxMed
What does AIxMed do?
AIxMed develops and sells AI-powered computational digital cytology software platforms that analyze whole slide images (WSI) to detect cancer cells. Its lead product, AIxURO, performs AI-assisted urine cytology analysis for bladder cancer detection using The Paris System (TPS 2.0) criteria, identifying suspicious and atypical urothelial cells with quantitative measurements. The portfolio also includes AIxTHY for thyroid cancer detection (FNAC analysis using the Bethesda System), with AIxPAP (cervical) and AIxPUL (lung) in development. The platform integrates with multiple slide scanners and Laboratory Information Systems via an open API.
Is AIxMed a public or private company?
AIxMed is a private company. It is classified as venture growth investor backed and is currently operating.
When was AIxMed founded?
AIxMed was founded in 2018. It employs 11 to 50 people.
Where is AIxMed based?
AIxMed is headquartered in Santa Clara, United States, in the North America region.
How does AIxMed make money?
One revenue line is on record: AI Software Platform Licensing.
Who are AIxMed's main competitors?
Direct peers on record are Paige.AI, Ibex Medical Analytics and PathAI. Broad incumbents are Lumea, Roche Digital Pathology, Hologic, Danaher / Leica Biosystems and Hamamatsu Photonics. Emerging players are VolitionRx and Mindpeak.
Does AIxMed have an API?
No public API is recorded for AIxMed.
What industry is AIxMed in?
AIxMed's product category is AI Digital Pathology Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow. Its NAICS code is 621511 and its SIC code is 8071.